Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Acquisitions (2020 - 2021)

Anika Therapeutics (ANIK) has disclosed Acquisitions for 2 consecutive years, with $113000.0 as the latest value for Q4 2021.

  • Quarterly Acquisitions fell 84.77% to $113000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $113000.0 through Sep 2022, down 89.77% year-over-year, with the annual reading at $476000.0 for FY2021, 99.5% down from the prior year.
  • Acquisitions for Q4 2021 was $113000.0 at Anika Therapeutics, up from $11000.0 in the prior quarter.
  • The five-year high for Acquisitions was $93.0 million in Q1 2020, with the low at $2000.0 in Q2 2021.